Safety and Pharmacokinetic Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke

NCT00870844 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Ischemic Stroke

Interventions

DRUG: Lu AA24493 (CEPO)
DRUG: Placebo

Sponsor

H. Lundbeck A/S